Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company specializing in oncology, with a primary focus on developing innovative therapies for hard-to-treat cancers including solid tumors and hematological malignancies. Founded in 1995 and headquartered in Toronto, Canada, Helix BioPharma advances novel immuno-oncology treatments based on proprietary technology platforms, notably targeting the CEACAM6 protein overexpressed in various cancers. Its lead candidate, L-DOS47, is an antibody-enzyme conjugate designed to modify the acidic tumor microenvironment, aiming to enhance immune response and the efficacy of existing cancer therapies, specifically in non-small cell lung cancer and pancreatic cancer. The company has expanded its pipeline through strategic acquisitions and collaborations, developing additional candidates like LEUMUNA™ for post-transplant leukemia relapse and GEMCEDA™, an oral gemcitabine prodrug. Helix BioPharma operates globally with listings on multiple exchanges, reflecting its commitment to advancing cancer treatment options through targeted, mechanism-based therapies that address significant unmet medical needs.